IP Library Granted Patent US 9,815,824
Granted Patent B2
US 9,815,824 · App. 14/900,039 · Granted Nov 14, 2017

Kappa opioid agonists and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,815,824
App. No.
14/900,039
Granted
Nov 14, 2017
Kind
B2
Abstract

Provided are compounds of Formula I; and pharmaceutically acceptable salts and solvates thereof. The present disclosure relates to novel compounds and to their use as agonists of the kappa opioid receptor. The disclosure also relates to methods for preparation of the compounds and to pharmaceutical compositions containing such compounds. Kappa opioid agonists that exhibit full agonist properties at the kappa opioid receptor have been widely shown to be efficacious in preclinical models of pain, particularly visceral pain.

Claims (28)

1. A compound having the structure:

wherein:

R 1 is

R 2 is hydrogen;

R 3 is hydrogen;

R 4 is —X-POLY;

R 5 is hydrogen;

R 6 is hydrogen;

X is —O— or —OC(O)NH—;

POLY is —(CH 2 CH 2 O) n —Y;

n is 1 to 30; and

Y is hydrogen or substituted or unsubstituted lower alkyl;

and pharmaceutically acceptable salts and solvates thereof.

2. A compound selected from:

2-(3, 4-dichlorophenyl)-N-{(1S)-2-[(3S)-3-(2-methoxyethoxy)pyrrolidin-1-yl]-1-phenylethyl}-N-methylacetamide;

2-(3, 4-Dichlorophenyl)-N-{(1S)-2-[(3S)-3-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)pyrrolidin-1-yl]-1-phenylethyl}-N-methylacetamide;

(3S)-1-[(2S)-2-{[(3,4-Dichlorophenyl)acetyl](methyl)amino}-2-phenylethyl]pyrrolidin-3-yl{2-[2-(2-methoxyethoxy)ethoxy]ethyl}carbamate;

(3S)-1-[(2S)-2-{[(3,4-Dichlorophenyl)acetyl](methyl)amino}-2-phenylethyl]pyrrolidin-3-yl 2,5,8,11,14-pentaoxahexadecan-16-ylcarbamate; and

2-(3,4-Dichlorophenyl)-N-methyl-N-{(1S)-2-[(3S)-3-(2,5,8,11,14-pentaoxahexadecan-16-yloxy)pyrrolidin-1-yl]-1-phenylethyl}acetamide;

and pharmaceutically acceptable salts thereof.

3. A pharmaceutical composition comprising a compound of claim 1 and at least one pharmaceutically acceptable excipient.

4. A method of treating pain or inflammation comprising administering a compound of claim 1 to a patient in need thereof.

5. The compound of claim 1 , having the structure:

wherein:

n is 1 to 30;

R 10 is hydrogen; and

R 11 is —H, —CH 3 , or —CF 3 ;

and pharmaceutically acceptable salts and solvates thereof.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 039284 FRAME 0901. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 26, 2017
From: ANAND, NEEL K.; DUARTE, FRANCO J.; ZHANG, WEN; REN, ZHONGXU
To: NEKTAR THERAPEUTICS
Reel/Frame 044013/0346 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2016
From: ANAND, NEEL K.; DUARTE, FRANCO J.; ZHANG, WEN
To: NEKTAR THERAPEUTICS
Reel/Frame 039284/0901 →
SECURITY INTEREST Recorded Mar 15, 2016
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS A COLLATERAL AGENT
Reel/Frame 037990/0511 →